Healthcare
Jyong Biotech Ltd. Ordinary Shares(MENS)
Live Price
Offline$1.56
-2.50% today
1Y Change
-80.70%
Window
Jun 25, 2025 → Jun 17, 2026
- Market Cap
- $170.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +31.4%
- Dividend Yield
- 0.0%
Coverage: 246 bars · Jun 25, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Jyong Biotech Ltd. Ordinary Shares (MENS) is a Healthcare stock with a market cap of $170.00M and listed on NASDAQ. The stock last traded around $1.56 and down 80.7% across the available one-year price window (Jun 25, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +31.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +31.4%, free cash flow -39.3% with operating margin 0.0% and ROIC -2.5%. Stock Foundry combines MENS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +31.4%, while operating margin sits near 0.0%.
Benchmark Edge
MENS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MENS
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MENS Max Drawdown
-97.78%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MENS and SPY.
Company Overview
Jyong Biotech Ltd. Ordinary Shares
NASDAQ Global Select
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages
- Leadership
- Fu-Feng Kuo
- IPO Date
- Jun 17, 2025
- Employees
- 31
- Street Address
- 23F‑3, No. 95, Section 1, Xintai 5th Road
- Mailing
- New Taipei City, 221
- Region
- New Taipei City, TW
- Reporting Currency
- USD
- Investor Line
- 886 2 2732 5205
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- +31.4%
- Free Cash Flow
- -39.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 4.2%
- ROIC
- -2.5%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.62
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.